» Articles » PMID: 33586775

Low Inducibility of Latent Human Immunodeficiency Virus Type 1 Proviruses As a Major Barrier to Cure

Overview
Journal J Infect Dis
Date 2021 Feb 15
PMID 33586775
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

The latent reservoir for human immunodeficiency virus type 1 (HIV-1) in resting CD4+ T cells is a major barrier to cure. The dimensions of the reservoir problem can be defined with 2 assays. A definitive minimal estimate of the frequency of latently infected cells is provided by the quantitative viral outgrowth assay (QVOA), which detects cells that can be induced by T-cell activation to release infectious virus. In contrast, the intact proviral DNA assay (IPDA) detects all genetically intact proviruses and provides a more accurate upper limit on reservoir size than standard single-amplicon polymerase chain reaction assays which mainly detect defective proviruses. The frequency of cells capable of initiating viral rebound on interruption of antiretroviral therapy lies between the values produced by the QVOA and the IPDA. We argue here that the 1-2-log difference between QVOA and IPDA values in part reflects that the fact that many replication-competent proviruses are not readily induced by T-cell activation. Findings of earlier studies suggest that latently infected cells can be activated to proliferate in vivo without expressing viral genes. The proliferating cells nevertheless retain the ability to produce virus on subsequent stimulation. The low inducibility of latent proviruses is a major problem for the shock-and-kill strategy for curing HIV-1 infection, which uses latency-reversing agents to induce viral gene expression and render infected cells susceptible to immune clearance. The latency-reversing agents developed to date are much less effective at reversing latency than T-cell activation. Taken together, these results indicate that HIV-1 eradication will require the discovery of much more effective ways to induce viral gene expression.

Citing Articles

Immune-mediated strategies to solving the HIV reservoir problem.

Kulpa D, Paiardini M, Silvestri G Nat Rev Immunol. 2025; .

PMID: 39948261 DOI: 10.1038/s41577-025-01136-7.


CBP/p300 lysine acetyltransferases inhibit HIV-1 expression in latently infected T cells.

Horvath R, Sadowski I iScience. 2024; 27(12):111244.

PMID: 39640574 PMC: 11617383. DOI: 10.1016/j.isci.2024.111244.


Cognate antigen engagement induces HIV-1 expression in latently infected CD4 T cells from people on long-term antiretroviral therapy.

Moskovljevic M, Dragoni F, Board N, Wu F, Lai J, Zhang H Immunity. 2024; 57(12):2928-2944.e6.

PMID: 39612916 PMC: 11896817. DOI: 10.1016/j.immuni.2024.11.002.


Preservation of functionality, immunophenotype, and recovery of HIV RNA from PBMCs cryopreserved for more than 20 years.

Dyer W, Suzuki K, Levert A, Starr M, Lloyd A, Zaunders J Front Immunol. 2024; 15:1382711.

PMID: 39221258 PMC: 11361978. DOI: 10.3389/fimmu.2024.1382711.


Specific quantification of inducible HIV-1 reservoir by RT-LAMP.

Hossain T, Lungu C, de Schrijver S, Kuali M, Crespo R, Reddy N Commun Med (Lond). 2024; 4(1):123.

PMID: 38918506 PMC: 11199587. DOI: 10.1038/s43856-024-00553-4.


References
1.
Wang Z, Gurule E, Brennan T, Gerold J, Kwon K, Hosmane N . Expanded cellular clones carrying replication-competent HIV-1 persist, wax, and wane. Proc Natl Acad Sci U S A. 2018; 115(11):E2575-E2584. PMC: 5856552. DOI: 10.1073/pnas.1720665115. View

2.
Simonetti F, Sobolewski M, Fyne E, Shao W, Spindler J, Hattori J . Clonally expanded CD4+ T cells can produce infectious HIV-1 in vivo. Proc Natl Acad Sci U S A. 2016; 113(7):1883-8. PMC: 4763755. DOI: 10.1073/pnas.1522675113. View

3.
Bullen C, Laird G, Durand C, Siliciano J, Siliciano R . New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med. 2014; 20(4):425-9. PMC: 3981911. DOI: 10.1038/nm.3489. View

4.
Strain M, Gunthard H, Havlir D, Ignacio C, Smith D, Leigh-Brown A . Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence. Proc Natl Acad Sci U S A. 2003; 100(8):4819-24. PMC: 153639. DOI: 10.1073/pnas.0736332100. View

5.
Koizumi Y, Ohashi H, Nakajima S, Tanaka Y, Wakita T, Perelson A . Quantifying antiviral activity optimizes drug combinations against hepatitis C virus infection. Proc Natl Acad Sci U S A. 2017; 114(8):1922-1927. PMC: 5338374. DOI: 10.1073/pnas.1610197114. View